IDYAClinical Trials•prnewswire•
IDEAYA Biosciences Announces First-Patient-In for Phase 1/2 Combination Trial of IDE397, A Potential First-in-Class MAT2A Inhibitor, and Trodelvy® in MTAP-Deletion Non-Small Cell Lung Cancer
Sentiment:Positive (70)
Summary
(NASDAQ:IDYA) SOUTH SAN FRANCISCO, Calif., Sept. 4, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced they have enrolled their first patient with non-small cell lung cancer (NSCLC) in the ongoing Phase 1/2 combination trial of...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 4, 2025 by prnewswire